BioWorld

Oct. 21, 2008

Adventrx Restructures to Focus Efforts on ANX-530 and ANX-514

A year after lead product CoFactor (ANX-510) failed a Phase IIb trial, Adventrx Pharmaceuticals Inc. is restructuring to focus on its chemotherapy emulsion products, ANX-530 and ANX-514. (BioWorld Today) Read More

'Not a Slam-Dunk': FDA Panel to Review New Version of Myozyme

Study Describes Partner in Crime for Bcr-Abl Kinase

Singapore's S*BIO Adds $26M for Phase II Studies in Cancer

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 31, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026